FindTrial
Sign In

Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease

A Multi-center, Longitudinal, Observational Study of Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) to Establish the Rate, Characteristics, and Determinants of Disease Progression

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1080221699
Enrollment
3000
Registered
2012-01-23
Start date
2012-01-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autosomal dominant polycystic kidney disease (ADPKD)

Interventions

investigational material(s) Generic name etc : N/A INN of investigational material : Therapeutic category code : --- Other Dosage and Administration for Investigational material : N/A

Sponsors

Otsuka Pharmaceutical Dvelopment & Commercialization, Inc.
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Existing diagnosis of ADPKD by modified-Ravine criteria 2) Total kidney volume >= 300 cc/m height by ultrasound or >= 250 cc/m height by MRI

Exclusion criteria

Exclusion criteria: 1) Current or expected (within the next six months) interventions for the treatment of ADPKD affecting kidney volume

Design outcomes

Primary

MeasureTime frame
Correlation of change in total kidney volume with ADPKD-related outcomes every 1 year—

Secondary

MeasureTime frame
Patient-reported pain every 6 months SF-12 Scores every 6 months ADPKD-Impact Scale Scores every 6 months Cost of care every 6 months EuroQuol-5D Scores every 6 months—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026